ALFA Finder| Revenue growth | 17.5% YoY consolidated growth. |
|---|---|
| Margins | Operating EBITDA margin at 22.3% (consolidated). |
| Demand visibility | Steady hospital occupancy at 68.7% and diagnostic volume growth. |
Growth
Hospital revenues grew 19% to INR 2,187 Cr. Diagnostics gross revenue increased 10.2% to INR 407 Cr.
Outlook
Ongoing expansion includes robotic surgical systems and new specialized institutes for Myeloma, Lymphoma, and Neurosciences.
Risks
Hospital occupancy slightly dipped to 68.7% from 69% YoY. ARPOB growth was modest at 2.6%.
Last quarter's promises, checked
Delivered
- Guided ~22-23% EBITDA margin for Diagnostics → delivered 23.2% (= BEAT)
- Guided ~15% hospital revenue growth → delivered 19% (= BEAT)
- Guided 1.5-2% annual margin expansion → delivered 180bps increase (= BEAT)
Partly delivered
- Guided 150bps margin improvement for FY27 → delivered 22.3% vs 22.8% FY26 (= PARTIAL)
Investor Presentation filed with BSE, NSE: FORTIS. Summary written with AI assistance from the document.
Fortis Healthcare Ltd: key numbers
- Share price
- ₹771.40
- Market cap
- ₹58,237 Cr
- Revenue (annual)
- ₹9,128 Cr
- Net profit (annual)
- ₹1,042 Cr
- P/E (TTM)
- 56.1×Sector 54.5×
- Promoter holding
- 31.17%+0.00% QoQ
- FII holding
- 23.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fortis Healthcare Ltd
All →Fortis Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue INR 2,735 Cr (+17.3%), PAT INR 317 Cr (+4.0%, 11.6% margin); H1 revenue INR 5,280 Cr (+17.4%). Net debt/EBITDA 0.87x. Expansion via Suguna acquisition and SLJ Delhi agreement.
Fortis Healthcare Results Update
Fortis Healthcare released a press release on Q2 FY27 results, with consolidated revenue of INR 2,735 Cr up 17.3%. It also disclosed the Suguna Hospital acquisition and a 400+ bed Delhi hospital services agreement.
- hospital beds acquired
- 110.0 beds
Fortis Healthcare Q2 FY27 Results: Net Profit ₹320.5 Cr, Down 2.5% YoY
Fortis Healthcare approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026 at its board meeting on November 5, 2026. The filing encloses the results and a limited review report with an emphasis on a SFIO fraud investigation.
- Key figure
- Net profit ₹320.5 Cr · -2.5% YoY
Fortis Healthcare Management Change
Fortis Healthcare's Chief Growth & Innovation Officer, Dr. Ritu Garg, resigned effective close of business on October 31, 2026. The resignation is a senior management personnel change with no monetary impact stated.
Fortis Healthcare Board Meeting Date
Fortis Healthcare will hold a board meeting on 5 November 2026 to approve Q2 and half-year unaudited results and alter terms of ₹1,550 Crore listed NCDs. The filing is a prior intimation of the board meeting with agenda items only.
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr